Lupin launches all-in-one inhaler for COPD patients in India
What Happened
Pharmaceutical major Lupin has launched a fixed-dose triple combination inhaler for Chronic Obstructive Pulmonary Disease (COPD) in India. The inhaler combines three therapies in a single device, offering a more convenient treatment option for patients with chronic respiratory conditions.
Key Takeaways
The launch strengthens Lupin's presence in the respiratory-care segment and could help improve treatment adherence by reducing the need for multiple inhalers among COPD patients.